Detection of CTLA-4 level and humeral immune response after the second dose of COVID-19 vaccine in certain Iraqi provinces participants

• Published in: PloS one Vol. 19; no. 1; p. e0296521
• Main Authors: Al-Kaif, Laith A I K, Al-Ameri, Hussain, Alfatlawi, Wael Rasheed Obaead, Mahdi, Ammar Eesa, Al-Khafaji, Younis A K, Al-Saadi, Mohammad Abd-Kadhum, Al-Charrakh, Alaa H, Al-Mammori, Raheem T, Akkaif, Mohammed Ahmed
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 05-01-2024; Public Library of Science (PLoS)
• Subjects: Analysis; Antibodies; Antibodies, Viral; Antigens; B cells; Cells; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; CTLA-4 Antigen; CTLA-4 protein; Cytokines; Disease transmission; Effectiveness; Enzyme-linked immunosorbent assay; Gram-positive bacteria; Health aspects; Health promotion; Humans; Humerus; Immune response; Immune status; Immune system; Immunity; Immunity, Humoral; Immunoglobulin G; Immunoglobulin M; Immunology; Infection; Infections; Iraq - epidemiology; Laboratories; Lymphocytes; Pandemics; Patients; Proteins; Public health; Questionnaires; SARS-CoV-2; Serology; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Ticagrelor; Vaccination; Vaccine efficacy; Vaccines; Viral infections; Iraq; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0296521

Evaluating immune responses following COVID-19 vaccination is paramount to understanding vaccine effectiveness and optimizing public health interventions. This study seeks to elucidate individuals' immune status after administering a second dose of diverse COVID-19 vaccines. By analyzing immune responses through serological markers, we aim to contribute valuable insights into the uniformity of vaccine performance.
A total of 80 participants were enrolled in this study, with demographic and COVID-19 infection-related data collected for categorization. Serum samples were acquired within a specified timeframe, and SARS-CoV-2 IgM/IgG rapid tests were conducted. Moreover, CTLA-4 levels were measured through ELISA assays, allowing us to assess the immune responses comprehensively. The participants were divided into eight groups based on various factors, facilitating a multifaceted analysis.
The outcomes of our investigation demonstrated consistent immune responses across the diverse types of COVID-19 vaccines administered in Iraq. Statistical analysis revealed no significant distinctions among the vaccine categories. In contrast, significant differences were observed in CTLA-4 among the control group (non-infected/non-vaccinated, infected/non-vaccinated) and infected/Pfizer, non-infected/Pfizer, and infected/Sinopharm, non-infected/sinopharm (P = 0.001, < 0.001, 0.023, respectively). This suggests that these vaccines exhibit comparable effectiveness in eliciting an immune response among the study participants.
In conclusion, our study's results underscore the lack of discriminatory variations between different COVID-19 vaccine types utilized in Iraq. The uniform immune responses observed signify the equitable efficacy and performance of these vaccines. Despite minor quantitative discrepancies, these variations do not hold statistical significance, reaffirming the notion that the various vaccines serve a similar purpose in conferring protection against COVID-19.